急性失代偿性心力衰竭患者应用缬沙坦的疗效及对血清肌钙蛋白T和超敏C反应蛋白的影响

Effect of Acute Decompensated Heart Failure Patients with Valsartan and Influence on Serum CardiacTroponin T and High Sensitive C Reactive Protein

目的:观察缬沙坦对急性失代偿性心脏衰竭(ADHF)患者的临床疗效以及对患者血液中心肌肌钙蛋白T(cTnT)和超敏C-反应蛋白(hsCRP)含量的影响。方法:选取笔者所在医院收治的76例急性失代偿性心脏衰竭ICU患者,采用随机数字表法将其分为缬沙坦组和对照组,各38例。对照组患者接受常规基础治疗,缬沙坦组在对照组基础上加用缬沙坦治疗,观察并比较两组患者住院期间的病死率、心力衰竭恶化和重复情况、ICU住院时间、不良反应情况,同时检测两组患者cTnT、hs-CRP的变化。结果:缬沙坦组患者在ICU住院时间明显少于对照组,差异有统计学意义(P<0.05)。治疗前比较,两组患者血液内cTnT及hs-CRP含量水平均明显下降,差异有统计学意义(P<0.05);且缬沙坦组低于对照组,差异有统计学意义(P<0.05)。结论:在常规基础治疗的同时加用缬沙坦,可明显降低ADHF患者心力衰竭的反复次数,缩短ADHF患者的住院时间,其药理作用机制有可能是缬沙坦可明显降低患者血清中cTnT和hs-CRP的水平。

Objective：To observe the effect of valsartan in acutedecompensated heart failure （ADHF） in patients with clinical efficacy as well as to the blood center in patients with cardiac troponin T（cTnT） and high sensitive C-reactive protein（hs-CRP） content influence.Method：76 case of patients with acute decompensated heart failure were treated in author’s hospital,were randomly divided into valsartan group and control group,38 cases in each. The control group received routine treatment,valsartan group was treated with valsartan in the treatment ofobservation period,and mortality,heart failuredeterioration rate and the number of iterations,ICU ward hospitalization,adverse reactions were compared between two groups of patients,and to detect changes in two groups of patients cTnT,hs-CRP.Result：Valsartan group patients in the ICU ward hospitalization time was less than that in the control group,the difference was statistically significant（P〈0.05）. Comparison of two groups of patients before treatment,blood cTnT and hs-CRP levels were significantly decreased,the difference was statistically significant（P〈0.05）;and valsartan group was lower than the control group,the difference was statistically significant（P〈0.05）.Conclusion：At the same time the routine treatment plus valsartan,repetition can significantly reduce heart failure in patients with ADHF,shorten the time ofhospitalization in patients with ADHF,its pharmacological mechanism may be valsartan can significantly reduce cTnT and CRP level in the serum of patients with.